In the software world, "move fast and break things" is a badge of honor. If your code is buggy, you push a patch. If your user interface is clunky, you A/B test a new one. If your entire product misses the mark, you pivot.
But in life sciences, there is no "undo" button.
When a Phase 3 trial fails because of poor patient selection or an ill-defined primary endpoint, you don’t get to iterate. You get a press release that wipes out 80% of your market cap, followed by a liquidation process. The explosions in this industry are bigger, the fuses are longer, and the window for correction is essentially non-existent.
I recently read a compelling analysis by David H. Crean titled Mistakes That Jeopardize Life Sciences Startups. David translates Paul Graham’s classic Y Combinator startup-killer framework into the high-stakes language of biotech, and this article is my Fractional CMO interpretation of those expert insights through the lens of commercial viability.
As a Fractional CMO, I look at these mistakes through a specific lens: the lens of commercial viability. My job is to tell you that "good science" isn’t enough. Most biotech startups don’t fail because the lab work was wrong; they fail because the business strategy around the lab work was non-existent.
The Iteration Lie: Tech vs. Life Sciences
The tech world’s "Minimum Viable Product" (MVP) does not exist in drug development. You cannot ship a "minimum viable molecule" to patients. The regulatory environment imposes a rigid, sequential sequence on value creation: Preclinical to IND, Phase 1 to Phase 3, and finally NDA/BLA.
In tech, the risk is distributed. In biotech, the risk is back-loaded.
From a Life Sciences Strategy perspective, this means your commercial strategy must be front-loaded. You cannot wait until you have FDA approval to ask, "Who is going to pay for this?" If you haven't integrated market access and payer strategy into your clinical trial design from Day 1, you are effectively flying a plane without landing gear.
The Fatal Three: Commercial Sins in the C-Suite
In David’s analysis, he identifies several "Fatal" risks. From a Fractional CMO’s perspective, three of these stand out as the silent killers of otherwise brilliant companies.
1. Marginal Unmet Medical Need (Mistake 03)
This is a classic "Value Proposition" failure. Many scientific founders get enamored with the elegance of a specific mechanism of action without asking if the market actually cares.
If you are chasing an indication with a tiny patient population and weak payer willingness-to-pay, you have a hobby, not a business. Conversely, if you are chasing a massive market like oncology but can’t demonstrate a clear differentiation from the entrenched standard of care, you’re invisible.
Incitrio has worked with several biotech and medical device firms to solve this exact problem. We don't just look at the science; we look at the "So What?" factor. If you can’t articulate your differentiation in one crisp sentence, you aren't ready for a term sheet.
2. The Me-Too Molecule (Mistake 04)
Incremental improvements are the death of venture-backed biotech. Big Pharma BD teams are sophisticated. They don't want a "slightly better" version of what they already have. They want breakthroughs.
If your molecule offers a 5% improvement in dosing convenience but no meaningful change in safety or efficacy, you will lose at the payer negotiation table. Differentiation must be defensible across clinical, regulatory, and commercial vectors simultaneously. This is where Biotech GTM (Go-To-Market) strategy becomes a survival skill.
3. No Defined Patient, Prescriber, or Payer Strategy (Mistake 10)
This is where the "Tech vs. Bio" divide is most dangerous. In tech, you find your users. In biotech, your "user" is a complex ecosystem of a patient (who needs it), a prescriber (who must be convinced to write it), and a payer (who must agree to fund it).
If you treat reimbursement as a "post-approval problem," you are likely handing your asset to a competitor. Market access strategy must be developed in parallel with clinical strategy. Your Phase 2 and 3 endpoints should be designed not just to satisfy the FDA, but to satisfy the insurance companies.
The Single-Discipline Founder Trap
One of the most frequent mistakes (Mistake 01) is the solo scientist founder without commercial fluency.
The "single-discipline" founder creates a massive blind spot. Boards and investors demand dual fluency: the ability to read a clinical dataset and a cap table with equal authority. A PhD who cannot communicate value to capital markets is a liability. An MBA who doesn't understand pipeline risk is a danger.
This is precisely where a Fractional CMO fits into the leadership structure. We provide that "commercial fluency" as a service, acting as a strategic bridge between the lab and the market. We ensure that the brand intelligence is baked into the development process, so the science has a vehicle that can actually carry it to the finish line.
Clinical Rigidity: Refusing to Read the Data
The biotech graveyard is littered with companies that ignored early signal failures. This is "Strategic Rigidity."
In a recent project for a mid-sized medical diagnostics firm, we observed a team clinging to an original indication despite emerging data suggesting a more lucrative, less crowded pivot. It took a firm, outside perspective: rooted in market reality: to force the conversation.
The best clinical-stage companies treat their programs as learning engines. If the data suggests your primary endpoint is unreachable, but a secondary biomarker signal is screaming "Success," you must have the organizational agility to pivot. If you wait for the Board to force the conversation, it’s usually too late.
The Liquidity Cliff: Undercapitalized to the Next Inflection Point
Mistake 11 in David’s framework is the cardinal rule of biotech: Raise enough capital to reach your next value-creating milestone, with a 12-month buffer beyond it.
Nothing destroys deal value faster than an obvious liquidity cliff. If you are six months away from your data readout and your bank account is empty, you are not negotiating from a position of strength. You are in a distressed M&A situation.
From a marketing and communications standpoint, your job is to manage investor expectations so that the "data speaks for itself" without the background noise of financial desperation. This requires a sophisticated IR and corporate communications strategy that builds credibility long before the data hits the wire.
Final Thought: The Integrated Obligation
Most biotech startups don’t fail because the science was wrong. They fail because the science was right, but the infrastructure around it: the team, the GTM strategy, the capital structure: wasn't built to shepherd it.
At Incitrio, we’ve seen this play out across the commercial and professional services landscapes. The founders who build enduring companies are those who treat scientific rigor and business discipline as a single, integrated obligation.
Don’t let your brilliant science die in the "Valley of Death" because of a missing commercial perspective. Whether it's refining your value prop for investors or building a payer-ready clinical strategy, the time to start is now: not after the IND.
If you’re navigating a strategic inflection point in the life sciences space, let’s talk. We help bridge the gap between the lab and the market.
Source: David H. Crean, "Mistakes That Jeopardize Life Sciences Startups."
